7 Biotechnology Stocks to Sell Now

GHDX, ACOR, AMRN, EXEL, TSRX, DSCO, ACHN slump in weekly rankings

   
7 Biotechnology Stocks to Sell Now

This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Genomic Health (NASDAQ:GHDX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. GHDX also rates an F in Portfolio Grader’s specific subcategory of Earnings Revisions. The trailing PE Ratio for the stock is 167.80. For a full analysis of GHDX stock, visit Portfolio Grader.

This week, Acorda Therapeutics’ (NASDAQ:ACOR) rating worsens to a D from the company’s C rating a week ago. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

The rating of Amarin (NASDAQ:AMRN) declines this week from a C to a D. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of May 8, 2013, 18% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.

Exelixis’ (NASDAQ:EXEL) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of May 8, 2013, 20.4% of outstanding Exelixis shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Trius Therapeutics (NASDAQ:TSRX) earns a D this week, moving down from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Discovery Laboratories (NASDAQ:DSCO) experiences a ratings drop this week, going from last week’s C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. The stock price has dropped 28.6% over the past month, worse than the 4.9% increase the Nasdaq has seen over the same period of time. For a full analysis of DSCO stock, visit Portfolio Grader.

The rating of Achillion (NASDAQ:ACHN) slips from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of May 8, 2013, 12.8% of outstanding Achillion shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/05/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-5/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.